SYNERGY MEGATRON™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SYNERGY MEGATRON Synchronous drug elution image.

Introducing SYNERGY MEGATRON

The SYNERGY MEGATRON™ BP Stent design features best-in-class strength, unmatched overexpansion, maximum visibility and uniform lesion scaffolding.

The SYNERGY MEGATRON BP Stent is a versatile model that can expand from 3.5 mm to 6.0 mm for tapered vessels.

Indicated for use in high bleeding risk patients.

Unlike permanent polymer DES technology, the SYNERGY MEGATRON BP Stent features synchronous drug elution and polymer absorption.

A New Type Of Stent

The SYNERGY MEGATRON Stent System is purpose built for large proximal vessels so you can maximize performance where it is needed most.

Receive Updates

Directions for Use

Indications, Safety, and Warnings

Modern PCI Treat Portfolio

Explore

Best-in-Class Axial & Radial Strength

Overall Strength in Perspective^*

Axial Strength
To maintain stent integrity in complex interventions.

Radial Strength
To maintain vessel patency.

All trademarks are property of their respective owners.
* Based on bench test data comparing to largest nominal diameter; 4.0 mm for Xience Sierra and 5.0 mm for SYNERGY MEGATRON and Resolute Onyx. N=3 minimum. Data on file. Bench test results not necessarily indicative of clinical performance.

† SYNERGY MEGATRON 5.0 mm diameter vs. Resolute Onyx 5.0 mm diameter. (N=3 minimum). Bench tests performed by Boston Scientific Corporation. Data on file. Bench test results not necessarily indicative of clinical performance.

Unmatched Overexpansion Range

Accommodate Wide Diameter Mismatch
A versatile stent model that can expand 2.5 mm, from 3.5 mm to 6.0 mm, to accommodate wide diameter mismatch.

Accommodate Wide Diameter Mismatch Graph

‡ Expansion information pulled from individual DFU documents for: SYNERGY MEGATRON Stent System, SYNERGY XD Stent System, Resolute Onyx Stent System, Xience Sierra Stent System, Orsiro Stent System.br>

Maximum Visibility

Platinum Chromium (PtCr) Alloy
Enhances visibility to aid in accurate stent placement.

§ 3.5 mm stent products tested under 6.0 mm copper phantom to stimulate body mass. Bench testing performed by Boston Scientific Corporation. Data on file. Bench test results not necessarily indicative of clinical performance.
** SYNERGY MEGATRON angiography image provided from Golden Jubilee Hospital.

Uniform Lesion Scaffolding

Maximize Lumen Gain
12-peak design minimizes tissue prolapse and maintains lumen diameter.

33% less tissue prolapse, 12-peak stent design to minimize tissue prolapse and maintaine lumen diameter

†† Compared to a 9-peak prototype DES. Bench testing performed by Boston Scientific Corporation. Data on file. Bench test and computational model results may not necessarily be indicative of clinical performance.

High Bleeding Risk Patients

Leading on Studying Short DAPT

The SYNERGY MEGATRON BP Stent can be safely used in conjunction with shortened DAPT in patients at high risk for bleeding (HBR), based on the results from the EVOLVE Short DAPT Trial.^‡‡1 This trial data, in conjunction with the HBR indication, provides important evidence to inform decisions about DAPT duration for this patient subset.

EVOLVE Short DAPT Trial^{‡‡ 1}

Studying 3-month DAPT in high bleeding risk patients

‡‡ EVOLVE Short DAPT is a prospective, multicenter, single-arm trial defining the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY BP Stent. Approximately 74% of patients enrolled discontinued DAPT at 3-months. N=1,396 (patients with respective event or sufficient follow-up). Co-primary endpoints: ARC Def/Prob ST and Death/MI from 3-15 months. High risk bleeding subjects were defined as meeting one or more of the following criteria: ≥75 years of age and, in the opinion of the investigator, the risk of bleeding associated with >3 months of DAPT outweighs the benefit; need for chronic or lifelong anticoagulation, history of major bleeding (severe/ life threatening or moderate bleeding based on the GUSTO classification) within 12 months of the index procedure; history of stroke (ischemic or hemorrhagic); renal insufficiency (creatinine ≥2.0 mg/dl) or failure (dialysis dependent); platelet count ≤100,000/μL.

1. Kirtane AJ, et al. Circ Cardiovasc Interv. 2021;14:e010144. doi:10.1161/CIRCINTERVENTIONS.120.010144

Ordering Information

ø(mm)	8	12	16	20	24	28	32	Overexpansion Capabilities
3.50	H7493942808350	H7493942812350	H7493942816350	H7493942820350	H7493942824350	H7493942828350	H7493942832350	6.0
4.00	H7493942808400	H7493942812400	H7493942816400	H7493942820400	H7493942824400	H7493942828400	H7493942832400	6.0
4.50	H7493942808450	H7493942812450	H7493942816450	H7493942820450	H7493942824450	H7493942828450	H7493942832450	6.0
5.00	H7493942808500	H7493942812500	H7493942816500	H7493942820500	H7493942824500	H7493942828500	H7493942832500	6.0